Lantern Pharma Unveils PredictBBB.ai With 94% Accuracy, Revolutionizing CNS Drug Development Through Real-Time AI

• Industry-Leading Platform Achieves 94% Accuracy with Real-Time Machine Learning, Providing Open-Access to Critical CNS Drug Development Technology
• Additional Predictive, Analytic and Descriptive Modules are Planned for Release Leveraging Lantern's Large-Scale Molecular Features Data Lake and Proprietary Ensemble Algorithmic Approach

Lantern Pharma Inc. (NASDAQ:LTRN), a pioneering artificial intelligence company transforming oncology drug discovery and development, today announced the public release of its AI module for predicting blood-brain barrier (BBB) permeability of small molecules with unprecedented accuracy and scalability – predictBBB.ai™. This critical advancement addresses one of pharmaceutical development's most persistent challenges—that only 2-6% of small-molecule drugs can successfully cross the blood-brain barrier—while establishing new industry benchmarks for computational drug discovery platforms.

The transformative technology leverages billions of molecular feature data points across millions of compounds within Lantern's proprietary molecular features data lake, enabling real-time ensemble algorithm processing that delivers 94% prediction accuracy with 95% sensitivity and 89% specificity. This represents a fundamental breakthrough in computational approaches to the development of molecules that need to reach the central nervous system (CNS), particularly significant given that the BBB technologies market is projected to expand from $1.4 billion in 2023 to $9.85 billion by 2032, reflecting urgent clinical demand for innovative and accessible solutions.